HIGHLIGHTS:
-
Arovella's CAR19-iNKT cell therapy will be combined with Imugene's onCARlytics (CF33- CD19) platform to target solid cancers in a pre-clinical trial.
-
This trial will explore the potential of expanding the use of ALA-101 in solid tumours, which pose significant unmet need and account for more than 90% of all diagnosed cancers.
-
onCARlytics is a CD19-expressing oncolytic virus that enters tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19 targeting therapies.
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform for cancer treatment, is pleased to collaborate with clinical stage immune-oncology company Imugene Limited (ASX: IMU), using its onCARlytics platform. This will test Arovella’s CAR19-iNKT (ALA101) cell therapy with Imugene’s onCARlytics platform to seek and destroy solid tumours. The read out from the preclinical studies performed through the collaboration is expected in H1 2023.
For more information, download the attached PDF.
Download this document
